Nicolai Juul Birkbak

Citée par

	Toutes	Depuis 2020
Citations	29476	20481
indice h	63	55
indice i10	91	84

4400

2200

1100

3300

201120122013201420152016201720182019202020212022202320242025159 232 294 477 642 885 1380 1990 2634 3540 4350 4120 3990 3959 512

Accès public

Tout afficher

88 articles

3 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Charles SwantonFrancis Crick InstituteAdresse e-mail validée de crick.ac.uk
Zoltan SzallasiHarvard Medical SchoolAdresse e-mail validée de childrens.harvard.edu
Aron Charles EklundClinical Microbiomics A/SAdresse e-mail validée de clinical-microbiomics.com
Nicholas McGranahanGroup Leader, CRUK Lung Cancer Centre of Excellence, UCL Cancer InstituteAdresse e-mail validée de ucl.ac.uk
Andrea L RichardsonAssociate Professor of Pathology and Oncology, Johns Hopkins University School of MedicineAdresse e-mail validée de jhmi.edu
Hugo AertsDirector AI in Medicine (AIM) @ Harvard-MGB | Professor @ MaastrichtUAdresse e-mail validée de dfci.harvard.edu
Qiyuan LiSchool of Medicine, Xiamen UniversityAdresse e-mail validée de xmu.edu.cn
Andrew J RowanPrincipal Laboratory Research Scientist, Francis Crick InstituteAdresse e-mail validée de crick.ac.uk
Benjamin Haibe-KainsScientist (Principal Investigator), Princess Margaret Cancer Centre, University Health NetworkAdresse e-mail validée de uhnresearch.ca
John QuackenbushHarvard T.H. Chan School of Public Health, Channing Division of Network Medicine, and Dana-FarberAdresse e-mail validée de hsph.harvard.edu
Francesco FaveroCopenhagen UniversityAdresse e-mail validée de bric.ku.dk
Chris AbboshAstraZenecaAdresse e-mail validée de astrazeneca.com
Marcin KrzystanekAssistant Professor, Technical University of DenmarkAdresse e-mail validée de cbs.dtu.dk
Mariam Jamal-HanjaniUCL Cancer InstituteAdresse e-mail validée de doctors.org.uk
Andrew H. BeckCo-Founder and CEO at PathAIAdresse e-mail validée de PathAI.com
Andrea Marion MarquardPostdoc, Technical University of DenmarkAdresse e-mail validée de dtu.dk
Gareth WilsonFrancis Crick Institute, UCL Cancer InstituteAdresse e-mail validée de crick.ac.uk
Rebecca A BurrellUniversity of CambridgeAdresse e-mail validée de cruk.cam.ac.uk
Prof Marco GerlingerBarts Cancer Institute, London, UKAdresse e-mail validée de qmul.ac.uk
Kevin LITCHFIELDResearch Leader - Isomorphic Labs (Alphabet company), Honorary Group Leader - UCLAdresse e-mail validée de google.com

Suivre

Nicolai Juul Birkbak

Professor, Department of Molecular Medicine (MOMA), Aarhus University

Adresse e-mail validée de clin.au.dk - Page d'accueil

Cancer Immunology Bioinformatics Intratumor heterogeneity


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ... Science 351 (6280), 1463-1469, 2016	3185	2016
Tracking the evolution of non–small-cell lung cancer M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ... New England Journal of Medicine 376 (22), 2109-2121, 2017	2380	2017
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017	1860	2017
Artificial intelligence in cancer imaging: clinical challenges and applications WL Bi, A Hosny, MB Schabath, ML Giger, NJ Birkbak, A Mehrtash, ... CA: a cancer journal for clinicians 69 (2), 127-157, 2019	1646	2019
Chromosomal instability drives metastasis through a cytosolic DNA response SF Bakhoum, B Ngo, AM Laughney, JA Cavallo, CJ Murphy, P Ly, P Shah, ... Nature 553 (7689), 467-472, 2018	1383	2018
Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017	1298	2017
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer DP Silver, AL Richardson, AC Eklund, ZC Wang, Z Szallasi, Q Li, N Juul, ... Journal of clinical oncology 28 (7), 1145-1153, 2010	1290	2010
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis S Turajlic, K Litchfield, H Xu, R Rosenthal, N McGranahan, JL Reading, ... The lancet oncology 18 (8), 1009-1021, 2017	935	2017
Neoantigen-directed immune escape in lung cancer evolution R Rosenthal, EL Cadieux, R Salgado, MA Bakir, DA Moore, CT Hiley, ... Nature 567 (7749), 479-485, 2019	827	2019
Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data F Favero, T Joshi, AM Marquard, NJ Birkbak, M Krzystanek, Q Li, ... Annals of Oncology 26 (1), 64-70, 2015	756	2015
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution N McGranahan, F Favero, EC De Bruin, NJ Birkbak, Z Szallasi, ... Science translational medicine 7 (283), 283ra54-283ra54, 2015	741	2015
Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal S Turajlic, H Xu, K Litchfield, A Rowan, S Horswell, T Chambers, ... Cell 173 (3), 595-610. e11, 2018	621	2018
Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents NJ Birkbak, ZC Wang, JY Kim, AC Eklund, Q Li, R Tian, C Bowman-Colin, ... Cancer discovery 2 (4), 366-375, 2012	605	2012
Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018	596	2018
Inconsistency in large pharmacogenomic studies B Haibe-Kains, N El-Hachem, NJ Birkbak, AC Jin, AH Beck, HJWL Aerts, ... Nature 504 (7480), 389-393, 2013	581	2013
Chromosomal instability confers intrinsic multidrug resistance AJX Lee, D Endesfelder, AJ Rowan, A Walther, NJ Birkbak, PA Futreal, ... Cancer research 71 (5), 1858-1870, 2011	541	2011
MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling SJ Song, L Poliseno, MS Song, U Ala, K Webster, C Ng, G Beringer, ... Cell 154 (2), 311-324, 2013	539	2013
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers CM Blakely, TBK Watkins, W Wu, B Gini, JJ Chabon, CE McCoach, ... Nature genetics 49 (12), 1693-1704, 2017	519	2017
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers S Trebeschi, SG Drago, NJ Birkbak, I Kurilova, AM Cǎlin, AD Pizzi, ... Annals of Oncology 30 (6), 998-1004, 2019	496	2019
Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017	455	2017

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs